Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sitaxsentan (ICOS-Texas Biotechnology).

J R Wu-Wong1

  • 1Abbott Laboratories, Santa Clara, CA 95054, USA. ruth.r.wuwong@abbott.com

Current Opinion in Investigational Drugs (London, England : 2000)
|September 22, 2001
PubMed
Summary

Sitaxsentan, an endothelin A receptor antagonist, is being developed for pulmonary hypertension and heart failure. Clinical trials are underway for various formulations and conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential for vitamin D receptor agonists in the treatment of cardiovascular disease.

British journal of pharmacology·2009
Same author

Vitamin D receptor: a highly versatile nuclear receptor.

Kidney international·2007
Same author

Statins do not directly activate vitamin D receptor.

Journal of thrombosis and haemostasis : JTH·2006
Same author

New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models.

Journal of medicinal chemistry·2001
Same author

A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors.

Cancer research·2001
Same author

Identification and characterization of A-105972, an antineoplastic agent.

Cancer research·2001

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Endothelin A (ETA) receptor antagonists represent a novel therapeutic class.
  • Sitaxsentan is under investigation for multiple cardiovascular and respiratory conditions.

Purpose of the Study:

  • To evaluate the safety and efficacy of sitaxsentan.
  • To explore sitaxsentan's potential in treating pulmonary hypertension, congestive heart failure (CHF), chronic obstructive pulmonary disease, and subarachnoid hemorrhage.

Main Methods:

  • Phase IIa trials for intravenous sitaxsentan in CHF.
  • Phase I safety trials for oral sitaxsentan formulation.
  • Planned Phase II/III trials for pulmonary hypertension.

Main Results:

  • Sitaxsentan has completed Phase I safety trials for oral administration.
  • Phase IIa trials are ongoing for intravenous administration in CHF patients.

Conclusions:

  • Sitaxsentan demonstrates potential as a therapeutic agent for cardiovascular and respiratory diseases.
  • Further clinical trials are required to establish its efficacy and safety profile across different indications.

Related Experiment Videos